Prescription drug costs are rising faster than inflation, and for Medicare beneficiaries, that is more than a budget concern. When specialty and biologic drugs run upwards of tens of thousands of dollars a year, patients are forced to choose between medication and basic household needs. The Medicare Part D redesign launched in 2025 under the Inflation Reduction Act aims to change that. The question is: how much relief it will really bring?
$2,000 Out-of-Pocket Cap
The new $2,000 annual out-of-pocket cap stems from the Inflation Reduction Act of 2022, which directed Medicare to redesign its Part D benefit beginning in 2025. Previously, Medicare beneficiaries faced unlimited exposure once they entered the “catastrophic” coverage phase, paying 5% of drug costs indefinitely, an impossible burden for anyone prescribed high-cost specialty therapies.
The new cap eliminates the cost of ongoing coinsurance and establishes a predictable spending limit. According to HHS, this change will benefit more than 11 million Medicare enrollees, saving an average of $600 per person in 2025 and more than $7 billion collectively.
Coverage Gaps and Cost Shifts
The cap applies only to outpatient drugs under Part D, excluding many high-cost injectables and infusions billed under Part B. And while $2,000 is an improvement, it is still a financial strain for many seniors on fixed incomes.
The structure of Part D creates new challenges as well. Cost sharing is often calculated from gross list prices instead of net prices after rebates, meaning members never see the benefit of negotiated savings. This approach still rewards higher list prices rather than lower overall costs.
Slow Start for Drug Price Negotiations
It is notable that for the first time, Medicare can negotiate prices directly for a small list of high-cost drugs. The first ten will have Maximum Fair Prices in effect in 2026, with another fifteen following in 2027.
This is a major policy shift, but change will be slow. Each year, only a limited number of drugs enter the process, and legal challenges will likely cause delays. For patients, the relief will come gradually.
The Inflation Catch
The $2,000 cap will be indexed each year, projected to rise to $2,100 in 2026. While that maintains program stability, it may not keep pace with actual affordability if drug prices continue to climb faster than inflation. Plan sponsors may offset their risk by raising premiums or deductibles, which could reduce the benefit for many members.
As smaller Part D plans struggle to adapt, consolidation may reduce competition, limiting innovation and cost control.
Affordability Still Out of Reach
Even with these reforms, the key drivers of U.S. drug inflation remain: single-source drugs with no biosimilar competition, gross-to-net price gaps, and misaligned incentives throughout the supply chain. When just ten drugs account for one-quarter of total Part D spending, the challenge is structural, not situational.
Until transparency and clinical substitution become standard practice, Medicare’s redesign can only go so far.
Where RazorMetrics Fits In
The Medicare reforms are a step in the right direction, but affordability is not only a federal issue. Health plans, states, and employers face the same challenge: drugs that cost too much and a system that resists change.
RazorMetrics solves this problem through a physician-directed platform that identifies clinically appropriate, lower-cost alternatives. Our work includes biosimilar adoption, deprescribing, and polypharmacy management, all integrated within the prescriber’s normal workflow.
The result is the kind of savings and member relief that policymakers envision, delivered efficiently to plan sponsors desperate for guaranteed pharmacy cost containment.
